Organised by: 

Abstract
The role of biomarkers is increasingly recognized in heart failure (HF) management, for diagnosis, prognostication, and screening of high-risk patients. Beyond natriuretic peptides and troponins, the utility of novel, emerging biomarkers is less established. This document reflects the key points of a Heart Failure Association of the European Society of Cardiology (ESC) consensus meeting on biomarker monitoring in HF.
Contributors

Ilaria Spoletini
Author

Andrew J S Coats
Author

Michele Senni
Author

Giuseppe M C Rosano
Author
St Georges Medical School London , United Kingdom of Great Britain & Northern Ireland
